{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:35:24Z","timestamp":1781912124828,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T00:00:00Z","timestamp":1404259200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40273-014-0182-6","type":"journal-article","created":{"date-parts":[[2014,7,2]],"date-time":"2014-07-02T00:56:22Z","timestamp":1404262582000},"page":"699-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cost-Effectiveness Analysis of Qsymia for Weight Loss"],"prefix":"10.1007","volume":"33","author":[{"given":"Eric A.","family":"Finkelstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Karnawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,2]]},"reference":[{"key":"182_CR1","unstructured":"World Health Organization. WHO Consultation. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization; 2000. p 894."},{"key":"182_CR2","unstructured":"WHO. Obesity and overweight. 2013. http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/ . Accessed 11 Oct 2013."},{"issue":"5","key":"182_CR3","doi-asserted-by":"crossref","first-page":"w822","DOI":"10.1377\/hlthaff.28.5.w822","volume":"28","author":"EA Finkelstein","year":"2009","unstructured":"Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):w822\u201331.","journal-title":"Health Aff"},{"issue":"10","key":"182_CR4","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/JOM.0b013e3181f274d2","volume":"52","author":"EA Finkelstein","year":"2010","unstructured":"Finkelstein EA, daCosta DiBonaventura M, Burgess SM, Hale BC. The costs of obesity in the workplace. J Occup Environ Med. 2010;52(10):971\u20136.","journal-title":"J Occup Environ Med"},{"key":"182_CR5","unstructured":"NHLBI Obesity Education Initiative Panel. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: NHLBI; 2004."},{"issue":"10","key":"182_CR6","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jada.2007.07.017","volume":"107","author":"MJ Franz","year":"2007","unstructured":"Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107(10):1755\u201367.","journal-title":"J Am Diet Assoc"},{"issue":"1","key":"182_CR7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/01.JCN.0000317471.58048.32","volume":"24","author":"MW Turk","year":"2009","unstructured":"Turk MW, Yang K, Hravnak M, Sereika SM, Ewing LJ, Burke LE. Randomized clinical trials of weight-loss maintenance: a review. J Cardiovasc Nurs. 2009;24(1):58.","journal-title":"J Cardiovasc Nurs"},{"key":"182_CR8","doi-asserted-by":"crossref","unstructured":"Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess (Winchester, England). 2009;13(41):1\u2013190, 215\u2013357, iii\u2013iv. doi: 10.3310\/hta13410 .","DOI":"10.3310\/hta13410"},{"issue":"3","key":"182_CR9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjsurg.2009.11.007","volume":"200","author":"EH Livingston","year":"2010","unstructured":"Livingston EH. The incidence of bariatric surgery has plateaued in the US. Am J Surg. 2010;200(3):378\u201385.","journal-title":"Am J Surg"},{"key":"182_CR10","unstructured":"Centers for Disease Control and Prevention. Adult obesity facts. 2014. http:\/\/www.cdc.gov\/obesity\/data\/adult.html . Accessed 23 April 2014."},{"key":"182_CR11","unstructured":"U.S. Census Bureau, Population Division. Annual estimates of the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2012. 2013. http:\/\/factfinder2.census.gov\/faces\/tableservices\/jsf\/pages\/productview.xhtml?src=bkmk . Accessed 23 April 2014."},{"issue":"45","key":"182_CR12","first-page":"1061","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","unstructured":"Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. Morb Mortal Wkly Rep. 1997;46(45):1061\u20136.","journal-title":"Morb Mortal Wkly Rep"},{"key":"182_CR13","unstructured":"US FDA. Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. 2010. http:\/\/www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm228830.htm . Accessed 9 Sept 2013."},{"issue":"12","key":"182_CR14","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R Padwal","year":"2003","unstructured":"Padwal R, Li S, Lau D. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes. 2003;27(12):1437\u201346.","journal-title":"Int J Obes"},{"issue":"9555","key":"182_CR15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","volume":"369","author":"RS Padwal","year":"2007","unstructured":"Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007;369(9555):71.","journal-title":"Lancet"},{"key":"182_CR16","unstructured":"US FDA. Medication guide: Qsymia. 2012. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM312590.pdf . Accessed 23 April 2014."},{"issue":"9774","key":"182_CR17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341\u201352.","journal-title":"Lancet"},{"issue":"2","key":"182_CR18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297\u2013308.","journal-title":"Am J Clin Nutr"},{"key":"182_CR19","unstructured":"Fox J. Medicare should, but cannot, consider cost: legal impediments to a sound policy. Buffalo Law Rev. 2005;53."},{"key":"182_CR20","first-page":"515","volume":"64","author":"MS Kolber","year":"2009","unstructured":"Kolber MS. Opacity and cost effectiveness analysis in Medicare coverage decisions: health policy encounters administrative law. Food Drug Law J. 2009;64:515.","journal-title":"Food Drug Law J"},{"key":"182_CR21","unstructured":"UnitedHealth Group. UnitedHealth Group launches innovative alliance providing free access to programs that help prevent and control diabetes and obesity. 2010. http:\/\/www.unitedhealthgroup.com\/Newsroom\/Articles\/News\/UnitedHealth%20Group\/2010\/0414DiabetesObesity.aspx . Accessed 8 May 2014."},{"key":"182_CR22","volume-title":"National prescription audit","author":"IMS Health","year":"2012","unstructured":"Health IMS. National prescription audit. Ambler: IMS America; 2012."},{"key":"182_CR23","volume-title":"SF-36 health survey: manual and interpretation guide","author":"JE Ware","year":"2000","unstructured":"Ware JE, Kosinski M, Dewey JE, Gandek B. SF-36 health survey: manual and interpretation guide. Lincoln: Quality Metric Inc.; 2000."},{"issue":"9","key":"182_CR24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","volume":"42","author":"JE Brazier","year":"2004","unstructured":"Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851\u20139.","journal-title":"Med Care"},{"issue":"2","key":"182_CR25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jval.2011.09.008","volume":"15","author":"JW Hay","year":"2012","unstructured":"Hay JW, Katon WJ, Ell K, Lee P-J, Guterman JJ. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly hispanics with diabetes. Value Health. 2012;15(2):249\u201354.","journal-title":"Value Health"},{"issue":"4","key":"182_CR26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/CIRCEP.108.837294","volume":"2","author":"MR Reynolds","year":"2009","unstructured":"Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009;2(4):362\u20139.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"03","key":"182_CR27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1017\/S0033291705006896","volume":"36","author":"W Katon","year":"2006","unstructured":"Katon W, Russo J, Sherbourne C, Stein MB, Craske M, Fan M-Y, et al. Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med. 2006;36(03):353\u201363.","journal-title":"Psychol Med"},{"issue":"1","key":"182_CR28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-7-38","volume":"7","author":"M Bensink","year":"2007","unstructured":"Bensink M, Wootton R, Irving H, Hallahan A, Theodoros D, Russell T, et al. Investigating the cost-effectiveness of videotelephone based support for newly diagnosed paediatric oncology patients and their families: design of a randomised controlled trial. BMC Health Serv Res. 2007;7(1):38.","journal-title":"BMC Health Serv Res"},{"key":"182_CR29","unstructured":"StataCorp. Stata Statistical Software, release 13. College Station: StataCorp LP; 2013."},{"key":"182_CR30","unstructured":"Medi-Span. Price RX database. 2013. http:\/\/www.medispan.com\/drug-pricing-analysis-pricerx.aspx . Accessed 27 Sept 2013."},{"key":"182_CR31","unstructured":"Medicare. Fee schedule, payment and reimbursement benefit guideline, CPT code billing. Office visit CPT, E&M code fee schedule\u2014Florida Medicare. 2013. http:\/\/www.medicarepaymentandreimbursement.com\/2013\/01\/office-visit-cpt-e-code-fee-schedule.html . Accessed 17 Jan 2014."},{"issue":"2","key":"182_CR32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","volume":"8","author":"SD Grosse","year":"2008","unstructured":"Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165\u201378. doi: 10.1586\/14737167.8.2.165 .","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"182_CR33","unstructured":"XE.com. XE live exchange rates. 2014. http:\/\/www.xe.com . Accessed 24 Feb 2014."},{"key":"182_CR34","unstructured":"NICE. Chapter 8: Linking clinical guidelines to other NICE guidance. In: The guidelines manual. London: NICE; 2012."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-014-0182-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-014-0182-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-014-0182-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:12:39Z","timestamp":1551186759000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-014-0182-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,2]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1007\/s40273-014-0182-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,2]]}}}